Challenges and Opportunities in Diabetes Technology Evaluation: A Call for Collaboration

The rapid advancements in diabetes technology are outpacing traditional evaluation methods, creating a dilemma for patients and stakeholders in the field. With an increasing number of people relying on tools such as continuous glucose monitors and insulin pumps, the need for efficient and reliable evaluation methods is more crucial than ever.

A recent editorial published in the Journal of Diabetes Science and Technology highlights the necessity for collaboration between researchers, regulators, manufacturers, and patients to develop new standards of evidence that can keep pace with the innovation in the diabetes technology space. The clash between innovation and regulation often results in a delay in evaluation or the use of technologies without sufficient evidence, posing risks to patients.

Issues such as managing upgrades in software and hardware, the need for ongoing evidence for regulatory approvals, and the rise of “do-it-yourself” systems developed by patients underscore the challenges in the current landscape of diabetes technology research. While randomized controlled trials are considered the gold standard for data quality, their high cost and lengthy timelines can hinder innovation.

The authors of the editorial emphasize the importance of finding a balance between speed and reliability in evidence gathering, leveraging the expertise of stakeholders to meet the needs of patients and ensure the safety and effectiveness of diabetes technologies. By establishing agreements on appropriate standards of evidence for different innovations, the market access for new technologies can be accelerated while providing essential data for various stakeholders.

As the demand for access to diabetes technology continues to grow, it is crucial for the industry to adapt and evolve evaluation methods to meet the needs of patients and ensure the safety and efficacy of these life-saving technologies.